FilingReader Intelligence
Jingxin Pharma secures exclusive cariprazine license for China
August 7, 2025 at 05:27 PM UTC•By FilingReader AI
Jingxin Pharma obtained an exclusive patent license from Gedeon Richter for cariprazine formulations and API in mainland China. Cariprazine is an atypical antipsychotic for schizophrenia and bipolar disorder.
The company will pay milestone payments up to €530,000 contingent on regulatory approvals, plus sales royalties based on net sales.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002020•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Jingxin Pharmaceutical publishes news
Free account required • Unsubscribe anytime